Pipeline Overview

R&D
Pipeline

At AntiCancer Technologies, we are advancing proprietary drug discovery research focusing on the "mechanisms that stop cancer growth." Currently, we are developing inhibitors for three molecules involved in cancer cell proliferation and survival: Metabolic Enzyme "X," Receptor "Y," and Ubiquitin Ligase "Z." Each target holds potential as a new approach for intractable cancers and cancer types resistant to existing treatments. Based on findings from basic research, development is progressing through processes such as screening, activity evaluation, and optimization, with an eye toward application in clinical settings. Our research pipeline represents an innovative challenge to forge the future of cancer treatment.

Pipeline